Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML
- 15 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (4), 834-846
- https://doi.org/10.1158/0008-5472.can-20-1430
Abstract
Hypomethylating agents (HMA) have become the backbone of non-intensive AML/MDS treatment, primarily by virtue of their activity in patients with adverse genetics, e.g., monosomal karyotypes, often with losses on chromosome 7, 5 or 17. However, no comparable activity is observed with cytarabine (AraC), a cytidine analogue without DNA-hypomethylating properties. As evidence exists for compounding hypermethylation and gene silencing of hemizygous tumor suppressor genes (TSG), we thus hypothesized that this effect may preferentially be reversed by the HMA decitabine (DAC) and azacitidine (AZA). An unbiased RNA-seq approach was developed to interrogate DAC-induced transcriptome changes in AML cell lines with or without a deletion of chromosomes 7q, 5q or 17p. HMA treatment (DAC or AZA) preferentially upregulated several hemizygous TSG in this genomic region, significantly derepressing endogenous retrovirus (ERV)3-1 with promoter demethylation, enhanced chromatin accessibility, and increased H3K4me3 levels. DAC globally reactivated multiple transposable elements, with activation of the dsRNA sensor RIG-I and interferon regulatory factor (IRF)7. Induction of ERV3-1 and RIG-I mRNA was also observed during DAC treatment in vivo in serially sorted peripheral blood AML blasts. In patient-derived murine monosomal karyotype AML xenografts, DAC treatment resulted in superior survival rates compared to AraC. Collectively, these data demonstrate preferential gene derepression and ERV reactivation in AML with chromosomal deletions, providing a mechanistic explanation that supports the clinical observation of superiority of HMA over AraC in this difficult-to-treat patient group.Keywords
Other Versions
Funding Information
- Deutsche Forschungsgemeinschaft (192904750 - CRC 992, SPP1463 LU 429/8-2, FOR2674 A05/A09)
- DFG (SFB 992/1 2012)
- BMBF (031 A538A/A538C RBC, 031L0101B/031L0101C de.NBI-epi, 031L0106 de. STAIR)
This publication has 49 references indexed in Scilit:
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesisBlood, 2012
- Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7qPublished by Elsevier BV ,2011
- Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidineLeukemia, 2011
- Zyxin Is a Critical Regulator of the Apoptotic HIPK2-p53 Signaling AxisCancer Research, 2011
- Integrated Analysis of Gene Expression, CpG Island Methylation, and Gene Copy Number in Breast Cancer Cells by Deep SequencingPLOS ONE, 2011
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLOS ONE, 2010
- Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid MalignanciesCancer Research, 2009
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004